Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 90

Sort by

Sort Order Select

Journal Articles

Feasibility of Adjusting Risk Group and Risk Group-Based Therapy during Induction in the Treatment of B-Cell Acute Lymphoblastic Leukemia: Results from DFCI ALL Consortium Protocol 16-001

Lynda M. Vrooman, Yael Flamand, Melissa A. Burns, Victoria B. Koch, Sarah M. Cronholm, Sarah K. Hunt, Peter D. Cole, Lisa M. Gennarini, Marian H. Harris, Nobuko Hijiya, Justine M. Kahn, Kara M. Kelly, Bruno Michon, Andrew E. Place, Thai Hoa Tran, Jennifer J.G. Welch, Stephen E. Sallan, Lewis B. Silverman

Blood (2024) 144 (Supplement 1): 311.

https://doi.org/10.1182/blood-2024-208605

Published: 2024

Journal Articles

Household Material Hardship and Inpatient Days in Dana-Farber Cancer Institute (DFCI) Acute Lymphoblastic Leukemia (ALL) Consortium Trial 16-001

Blood (2024) 144 (Supplement 1): 3649.

https://doi.org/10.1182/blood-2024-199274

Published: 2024

Journal Articles

Efficacy and Toxicity of Fixed Dose Versus Reduced/PK-Adjusted Dose Pegaspargase in Pediatric Patients with Newly Diagnosed Acute Lymphoblastic Leukemia: Results of DFCI ALL Consortium Protocol 16-001

Melissa A. Burns, Yael Flamand, Lynda M. Vrooman, Victoria B. Koch, Yves Theoret, Sarah M. Cronholm, Sarah K. Hunt, Peter D. Cole, Lisa M. Gennarini, Nobuko Hijiya, Justine M. Kahn, Kara M. Kelly, Bruno Michon, Donna S. Neuberg, Andrew E. Place, Thai Hoa Tran, Jennifer J.G. Welch, Stephen E. Sallan, Lewis B. Silverman

Blood (2024) 144 (Supplement 1): 307.

https://doi.org/10.1182/blood-2024-207273

Published: 2024

Journal Articles

Advancing Nursing Care and Education for Sickle Cell Disease: A Quality Improvement Initiative

Hayley Kiander, Moniba Nazeef, Thorunn H. Thordardottir, Ashley Almburg, Gwen Klinkner, Lucy Lomeli, Eva K. Allen, Hanna Duncan-Dietrich, Alaina M. Kelly, Benjamin T. Schnapp, Wendy Curran

Blood (2024) 144 (Supplement 1): 7531.

https://doi.org/10.1182/blood-2024-208080

Published: 2024

Journal Articles

Pembrolizumab in Children, Adolescents, and Young Adults with High-Risk Classic Hodgkin Lymphoma (cHL) with Slow Early Response to Front-Line Chemotherapy: Updated Results from the Phase 2 Keynote-667 Study

Blood (2024) 144 (Supplement 1): 3055.

https://doi.org/10.1182/blood-2024-199675

Published: 2024

Journal Articles

Pembrolizumab in Children, Adolescents, and Young Adults with Low-Risk Classic Hodgkin Lymphoma (cHL) and Slow Early Response to Front-Line Chemotherapy: Updated Results from the Phase 2 Keynote-667 Study

Blood (2024) 144 (Supplement 1): 462.

https://doi.org/10.1182/blood-2024-199263

Published: 2024

Journal Articles

Public Insurance As a Proxy Measure of Household Poverty-Exposures Among Children with Hematologic Malignancies

Rahela Aziz-Bose, Morgan A. Paul, Yael Flamand, Colleen A. Kelly, Leanne Duhaney, Puja J. Umaretiya, Lucille Lokko, McKenzie Griffin, Alexandria Hawkins, Peter D. Cole, Lisa M. Gennarini, Justine M. Kahn, Kara M. Kelly, Victoria B. Koch, Bruno Michon, Thai Hoa Tran, Jennifer J.G. Welch, Lewis B. Silverman, Kira Bona

Blood (2024) 144 (Supplement 1): 3750.

https://doi.org/10.1182/blood-2024-205672

Published: 2024

Journal Articles

Oral Chemotherapy Adherence in Pediatric Acute Lymphoblastic Leukemia (ALL): A Report from the Dana-Farber Cancer Institute (DFCI) ALL Consortium Protocol 16-001

Justine M. Kahn, Hital Patel, Julia Keating, Yael Flamand, Victoria Koch, Peter D. Cole, Lisa M. Gennarini, Bruno Michon, Thai Hoa Tran, Jennifer J.G. Welch, Lewis B. Silverman, Elizabeth Bouchard, Kira Bona, Kara M. Kelly

Blood (2023) 142 (Supplement 1): 7375.

https://doi.org/10.1182/blood-2023-189447

Published: 2023

Journal Articles

BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 Study

Blood (2023) 142 (Supplement 1): 219.

https://doi.org/10.1182/blood-2023-181857

Published: 2023

Journal Articles

Pembrolizumab (pembro) in Children and Young Adults with Low-Risk Classical Hodgkin Lymphoma (cHL) with Slow Early Response (SER) to Front-Line Chemotherapy (chemo): Early Results from the Phase 2 Keynote-667 Study

Blood (2023) 142 (Supplement 1): 1700.

https://doi.org/10.1182/blood-2023-186719

Published: 2023

Journal Articles

The Splicing-Associated Network PAK1-Clk-SRRM1 Is a Critical Vulnerability to Overcome Chemoresistance in Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 409.

https://doi.org/10.1182/blood-2023-186264

Published: 2023

Journal Articles

Longitudinal Differences By Treatment Arm in Health-Related Quality of Life Among High Risk Pediatric Hodgkin's Lymphoma Patients Treated on the Children's Oncology Group Ahod 1331 Study

Annalynn M Williams, Angie Mae Rodday, Qinglin Pei, Tara O. Henderson, Frank Keller, Angela Punnett, Kara M. Kelly, Sharon M. Castellino, Susan K Parsons

Blood (2023) 142 (Supplement 1): 672.

https://doi.org/10.1182/blood-2023-187125

Published: 2023

Journal Articles

Prevalence and Spectrum of Autoimmune Diseases Among Patients with Telomere Biology Disorder

Alaina M Kelly, Lauren G Banaszak, Kelcy Smith-Simmer, Kyle Shoger, Sarah M Donohue, Erin Lowery, Jane E Churpek

Blood (2023) 142 (Supplement 1): 4110.

https://doi.org/10.1182/blood-2023-181333

Published: 2023

Journal Articles

Progression-Free Survival (PFS) and Toxicity with Nivolumab-AVD Compared to Brentuximab Vedotin-AVD in Pediatric Advanced Stage (AS) Classic Hodgkin Lymphoma (cHL), Results of SWOG S1826

Blood (2023) 142 (Supplement 1): 610.

https://doi.org/10.1182/blood-2023-180107

Published: 2023

Journal Articles

AHOD2131: A Randomized Phase 3 Response-Adapted Trial Comparing Standard Therapy with Immuno-Oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma

Blood (2023) 142 (Supplement 1): 3084.

https://doi.org/10.1182/blood-2023-189652

Published: 2023

Journal Articles

CNS Involvement in Pediatric Hodgkin Lymphoma: A Comprehensive Retrospective Analysis from the Staging, Evaluation and Response Criteria Harmonization (SEARCH) for Childhood, Adolescent and Young Adult Hodgkin Lymphoma (CAYAHL) Group

Reena Pabari, Kathleen McCarten, Jamie E. Flerlage, Hollie Lai, Christine Mauz-Koerholz, Karin Dieckmann, Monica Palese, Sue Caste, Sharon M. Castellino, Kara M. Kelly, Dietrich Stoevesandt, Lars Kurch

Blood (2023) 142 (Supplement 1): 3066.

https://doi.org/10.1182/blood-2023-187921

Published: 2023

Journal Articles

Identifying Tumor-Specific Immune Response and Biomarkers of High-Risk Hodgkin Lymphoma Patients Treated with and without Brentuximab on Children's Oncology Group Trial AHOD1331

Keri Toner, Hema Dave, Gloria Pezzella, Qinglin Pei, Terzah M. Horton, Kara M. Kelly, Lisa Giulino Roth, Sharon M. Castellino, Catherine M. Bollard

Blood (2023) 142 (Supplement 1): 4383.

https://doi.org/10.1182/blood-2023-180791

Published: 2023

Journal Articles

Implementation of a Best Practice Alert and Dedicated Hematology Consultation on Hospitalization Outcomes of Patients with Sickle Cell Disease

Alaina M Kelly, Moniba Nazeef, Fauzia Osman, Shannon Stiles, Eva K. Allen, Hayley Kiander, Wendy Curran, Benjamin Schnapp

Blood (2023) 142 (Supplement 1): 5058.

https://doi.org/10.1182/blood-2023-187936

Published: 2023

Journal Articles

Pembrolizumab (pembro) in Children and Young Adults with High-Risk Classical Hodgkin Lymphoma (cHL) with Slow Early Response (SER) to Front-Line Chemotherapy (chemo): Updated Results from the Phase 2 Keynote-667 Study

Christine Mauz-Koerholz, Auke Beishuizen, Luciana Vinti, Antony Ceraulo, Gerard Michel, Michaela Cepelova, Franca Fagioli, Constantino Sabado Alvarez, Stephane Ducassou, Salvatore Buffardi, Maitane Andión Catalan, Brad Hoppe, Frank Keller, Kara M. Kelly, Lisa Giulino Roth, Judith Landman-Parker, Juan Shen, Pallavi Pillai, Stephen Daw

Blood (2023) 142 (Supplement 1): 3063.

https://doi.org/10.1182/blood-2023-187028

Published: 2023

Journal Articles

Performance of Positron Emission Tomography at Diagnosis and Response Assessment in Low and Intermediate-Risk Nodular Lymphocyte Predominant Hodgkin Lymphoma

Lianna J. Marks, Kathleen McCarten, Qinglin Pei, Yue Wu, Kara M. Kelly, Cindy Schwartz, Suzanne Wolden, Debra L. Friedman, Sharon M. Castellino, Burton Appel

Blood (2023) 142 (Supplement 1): 1699.

https://doi.org/10.1182/blood-2023-179465

Published: 2023

NARROW

Feasibility of Adjusting Risk Group and Risk Group-Based Therapy during Induction in the Treatment of B-Cell Acute Lymphoblastic Leukemia: Results from DFCI ALL Consortium Protocol 16-001

Household Material Hardship and Inpatient Days in Dana-Farber Cancer Institute (DFCI) Acute Lymphoblastic Leukemia (ALL) Consortium Trial 16-001

Efficacy and Toxicity of Fixed Dose Versus Reduced/PK-Adjusted Dose Pegaspargase in Pediatric Patients with Newly Diagnosed Acute Lymphoblastic Leukemia: Results of DFCI ALL Consortium Protocol 16-001

Advancing Nursing Care and Education for Sickle Cell Disease: A Quality Improvement Initiative

Pembrolizumab in Children, Adolescents, and Young Adults with High-Risk Classic Hodgkin Lymphoma (cHL) with Slow Early Response to Front-Line Chemotherapy: Updated Results from the Phase 2 Keynote-667 Study

Pembrolizumab in Children, Adolescents, and Young Adults with Low-Risk Classic Hodgkin Lymphoma (cHL) and Slow Early Response to Front-Line Chemotherapy: Updated Results from the Phase 2 Keynote-667 Study

Public Insurance As a Proxy Measure of Household Poverty-Exposures Among Children with Hematologic Malignancies

Oral Chemotherapy Adherence in Pediatric Acute Lymphoblastic Leukemia (ALL): A Report from the Dana-Farber Cancer Institute (DFCI) ALL Consortium Protocol 16-001

BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 Study

Pembrolizumab (pembro) in Children and Young Adults with Low-Risk Classical Hodgkin Lymphoma (cHL) with Slow Early Response (SER) to Front-Line Chemotherapy (chemo): Early Results from the Phase 2 Keynote-667 Study

The Splicing-Associated Network PAK1-Clk-SRRM1 Is a Critical Vulnerability to Overcome Chemoresistance in Acute Myeloid Leukemia

Longitudinal Differences By Treatment Arm in Health-Related Quality of Life Among High Risk Pediatric Hodgkin's Lymphoma Patients Treated on the Children's Oncology Group Ahod 1331 Study

Prevalence and Spectrum of Autoimmune Diseases Among Patients with Telomere Biology Disorder

Progression-Free Survival (PFS) and Toxicity with Nivolumab-AVD Compared to Brentuximab Vedotin-AVD in Pediatric Advanced Stage (AS) Classic Hodgkin Lymphoma (cHL), Results of SWOG S1826

AHOD2131: A Randomized Phase 3 Response-Adapted Trial Comparing Standard Therapy with Immuno-Oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma

CNS Involvement in Pediatric Hodgkin Lymphoma: A Comprehensive Retrospective Analysis from the Staging, Evaluation and Response Criteria Harmonization (SEARCH) for Childhood, Adolescent and Young Adult Hodgkin Lymphoma (CAYAHL) Group

Identifying Tumor-Specific Immune Response and Biomarkers of High-Risk Hodgkin Lymphoma Patients Treated with and without Brentuximab on Children's Oncology Group Trial AHOD1331

Implementation of a Best Practice Alert and Dedicated Hematology Consultation on Hospitalization Outcomes of Patients with Sickle Cell Disease

Pembrolizumab (pembro) in Children and Young Adults with High-Risk Classical Hodgkin Lymphoma (cHL) with Slow Early Response (SER) to Front-Line Chemotherapy (chemo): Updated Results from the Phase 2 Keynote-667 Study

Performance of Positron Emission Tomography at Diagnosis and Response Assessment in Low and Intermediate-Risk Nodular Lymphocyte Predominant Hodgkin Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only